Pepvise
Kun til informasjon — ikke medisinsk råd. Pepvise-anmeldelser er i informasjonsøyemed. Det er ikke medisinske råd. Rådfør deg med forskriveren før du starter et peptidprotokoll.
Editorial illustration: a vial of tesamorelin beside a measuring tape; FDA-approved as Egrifta for HIV-associated lipodystrophy only.
Tesamorelin — Tesamorelin (GHRH analogue) · Research peptide (see review for regulatory status)
Tesamorelin (editorial illustration, not a product photo).
Image: PepVise editorial illustration via Wikimedia Commons (Public domain). Editorial use for educational purposes only.

Analysis

Theratechnologies-developed synthetic analogue of human GHRH. FDA-approved 2010 (as Egrifta) for the treatment of excess abdominal fat in HIV-infected adults with lipodystrophy. Subsequent investigation in NAFLD/NASH and metabolic indications.

Tesamorelin is a synthetic stabilised analogue of human GHRH(1-44) developed by Theratechnologies and approved by FDA in 2010 (brand: Egrifta) for the reduction of excess abdominal fat in HIV-infected adults with lipodystrophy. Falagas 2010 (Clin Infect Dis) and the subsequent Stanley 2014 (JAMA) trial are the key evidence base. The Phase 2/3 work in HIV-associated NAFLD/NASH (Stanley 2019, Lancet HIV) extends the dossier into liver-fat-reduction outcomes within the HIV cohort. Methodology v1.2 scores Tesamorelin 7.7, the highest score among the GHRH/GHRP class because it is the only molecule in the class with a regulated indication, an established supply chain through specialty pharmacies, and a full Phase 3 dossier. The score remains below the GLP-1 RAs because the trial population is narrow (HIV-associated lipodystrophy, not general weight management) and the off-label use the research-channel market promotes, anti-aging, general body-composition, athletic performance, has no supportive trial evidence. WADA prohibits tesamorelin under Class S2. Within its approved indication and supervised under specialist HIV care, tesamorelin is the most-validated peptide in the GHRH class. Outside that indication, the evidence base is thin.

SIDE OM SIDE

Topp fire på hver dimensjon.

Høyere er bedre. Tabulariske tall, metodikken på egen side, og ja — selgertillit teller fordi forfalskningsrisikoen er reell.

#FORBINDELSEEVIDENSMEKANISMEHUMANSELGERSIKKERHETTOTALT
6CJC-1295
GRF(1-29) analogue with DAC modification
5.57.53.04.55.55.2
7Ipamorelin
GHRP-class growth-hormone secretagogue
5.57.03.04.56.05.2
8Tesamorelin
synthetic GHRH analogue (Egrifta)
8.08.07.57.57.57.7
9Sermorelin
GHRH(1-29), formerly Geref
5.57.05.06.06.56.0

For og imot

DET SOM FUNGERERDET SOM IKKE FUNGERER
Falagas et al. 2010 and Stanley et al. 2014 are the key Phase 3 trials; the regulated indication is real and the Phase 4 surveillance dossier is meaningful.WADA-prohibited (S2), athletic-population sanctions risk.
NAFLD/NASH Phase 2/3 trials (Stanley 2019, Lancet HIV) extend the dossier into liver-fat reduction in the HIV population.Off-label prescribing for general anti-aging or fat-loss indications outside the approved HIV-lipodystrophy population is not supported by published trial evidence.
Established supply chain through regulated specialty pharmacies, the only GHRH-class peptide with a quality-controlled commercial route.Daily subcutaneous injection; adherence ceiling lower than weekly molecules.
Long-term safety record across HIV-lipodystrophy cohorts since 2010.Cost remains a meaningful barrier in non-insured contexts.

Testede alternativer

Tre forbindelser fra det samme sammenligningssettet.

Kilder

4 cited
  1. Falagas et al. 2010, Tesamorelin HIV-lipodystrophy Phase 3, Clin Infect Dis
  2. Stanley et al. 2014, Tesamorelin and visceral fat in HIV, JAMA
  3. Stanley et al. 2019, Tesamorelin for NAFLD in HIV, Lancet HIV
  4. FDA Drugs@FDA, Egrifta (tesamorelin) labeling
Sist testet
Vurdert med v1.2

Andre omtaler i denne kategorien